Abstract
The consequences of past COVID-19 infection for personal health and long-term population immunity are only starting to be revealed. Unfortunately, detecting past infection is currently a challenge, limiting clinical and research endeavors. Widely available anti-SARS-CoV-2 antibody tests cannot differentiate between past infection and vaccination given vaccine-induced anti-spike antibodies and the rapid loss of infection-induced anti-nucleocapsid antibodies. Anti-membrane antibodies develop after COVID-19, but their long-term persistence is unknown. Here, we demonstrate that anti-membrane IgG is a sensitive and specific marker of past COVID-19 infection and persists at least one year. We also confirm that anti-receptor binding domain (RBD) Ig is a long-lasting, sensitive, and specific marker of past infection and vaccination, while anti-nucleocapsid IgG lacks specificity and quickly declines after COVID-19. Thus, a combination of anti-membrane and anti-RBD antibodies can accurately differentiate between distant COVID-19 infection, vaccination, and naïve states to advance public health, individual healthcare, and research goals.
Competing Interest Statement
MFA, DHO, and MAS are listed as inventors on a patent filed related to the findings in this study (Application: PCT/US2021/051143. Title: IDENTIFICATION OF SARS-COV-2 EPITOPES DISCRIMINATING COVID-19 INFECTION FROM CONTROL AND METHODS OF USE. Application type: PCT. Status: Filed. Country: N/A. Filing date: September 20, 2021). LumitTM SARS-CoV-2 Immunoassay kits were provided at no cost by Promega.
Funding Statement
This work was supported by a Wisconsin Partnership Program COVID-19 Response grant (4647) and a UWSMPH Department of Medicine COVID-19 Pilot Award to MAS, by the Centers for Disease Control (75D30120C09870 and 75D30121C11060) to DHO and TCF, and by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (R24OD017850) to DHO. Additional support includes NIH National Institute on Aging (T32 AG000213) and Medical Scientist Training Program (T32 GM140935) to MFA, National Heart, Lung and Blood Institute (T32 HL007899) to AMM, National Center for Advancing Translational Sciences (1KL2TR002374) to SSM, and National Institute of Allergy and Infectious Diseases (1DP2AI144244-01) to NS. DHO and TCF are also members of the Upper Midwest Regional Accelerator for Genomic Surveillance funded by the Rockefeller Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Wisconsin gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the supplemental files.
